MX2017003304A - Veliparib en combinacion con carboplatino y paclitaxel para el tratamiento de cancer de pulmon de celulas no pequeñas en fumadores. - Google Patents

Veliparib en combinacion con carboplatino y paclitaxel para el tratamiento de cancer de pulmon de celulas no pequeñas en fumadores.

Info

Publication number
MX2017003304A
MX2017003304A MX2017003304A MX2017003304A MX2017003304A MX 2017003304 A MX2017003304 A MX 2017003304A MX 2017003304 A MX2017003304 A MX 2017003304A MX 2017003304 A MX2017003304 A MX 2017003304A MX 2017003304 A MX2017003304 A MX 2017003304A
Authority
MX
Mexico
Prior art keywords
veliparib
carboplatin
paclitaxel
treatment
combination
Prior art date
Application number
MX2017003304A
Other languages
English (en)
Inventor
Gordon Gary
GIRANDA Vicent
d mckee Mark
Qian Jane
Qin Qin
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017003304A publication Critical patent/MX2017003304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a un método para el tratamiento de cáncer de pulmón de células no pequeñas en un sujeto quien es un fumador, que comprende administrar al sujeto una cantidad efectiva de 2-[(2R)-2-metilpirrolidin-2-il]-1H-benzimidazol-4-carb oxamida (veliparib o ABT-888), o una sal farmacéuticamente aceptable de la misma, en combinación con carboplatino y paclitaxel.
MX2017003304A 2014-09-16 2015-09-16 Veliparib en combinacion con carboplatino y paclitaxel para el tratamiento de cancer de pulmon de celulas no pequeñas en fumadores. MX2017003304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051040P 2014-09-16 2014-09-16
PCT/US2015/050367 WO2016044384A1 (en) 2014-09-16 2015-09-16 Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

Publications (1)

Publication Number Publication Date
MX2017003304A true MX2017003304A (es) 2017-08-15

Family

ID=54207780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003304A MX2017003304A (es) 2014-09-16 2015-09-16 Veliparib en combinacion con carboplatino y paclitaxel para el tratamiento de cancer de pulmon de celulas no pequeñas en fumadores.

Country Status (15)

Country Link
US (2) US9623009B2 (es)
EP (1) EP3193861A1 (es)
JP (1) JP2017527627A (es)
KR (1) KR20170055536A (es)
CN (1) CN107073015B (es)
AU (1) AU2015317856B2 (es)
CA (1) CA2959175A1 (es)
CL (1) CL2017000636A1 (es)
DO (1) DOP2017000069A (es)
IL (1) IL250708A0 (es)
MX (1) MX2017003304A (es)
PH (1) PH12017500505A1 (es)
RU (1) RU2017112960A (es)
SG (1) SG11201702129XA (es)
WO (1) WO2016044384A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7033601B2 (ja) * 2017-01-05 2022-03-10 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞
WO2018187485A1 (en) * 2017-04-04 2018-10-11 The George Washington University Combination therapy for treating cancer
US20200129482A1 (en) * 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
EP2059802A4 (en) * 2006-09-05 2010-09-08 Bipar Sciences Inc METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF
EP2440203A4 (en) * 2009-06-04 2017-06-07 The Governors of the University of Alberta Small molecule inhibitors of polynucleotide kinase/phosphatase. poly(adp-ribose) polymerase and uses thereof
RU2014150506A (ru) * 2012-05-15 2016-07-10 Эббви Инк. Велипариб в комбинации с лучевой терапией всего мозга для лечения метастазов в головной мозг
JP6324381B2 (ja) * 2012-07-31 2018-05-16 クラウン バイオサイエンス インコーポレイテッド（タイカン） 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
US20140187537A1 (en) * 2013-01-03 2014-07-03 Emory University Methods of predicting outcomes of chemotherapy treatments and alternative therapies

Also Published As

Publication number Publication date
CA2959175A1 (en) 2016-03-24
CL2017000636A1 (es) 2017-11-03
US20170172985A1 (en) 2017-06-22
US9623009B2 (en) 2017-04-18
EP3193861A1 (en) 2017-07-26
KR20170055536A (ko) 2017-05-19
AU2015317856B2 (en) 2020-05-14
US20160074368A1 (en) 2016-03-17
PH12017500505A1 (en) 2017-08-30
SG11201702129XA (en) 2017-04-27
JP2017527627A (ja) 2017-09-21
CN107073015B (zh) 2020-07-21
DOP2017000069A (es) 2017-05-15
RU2017112960A (ru) 2018-10-17
AU2015317856A1 (en) 2017-03-16
IL250708A0 (en) 2017-04-30
WO2016044384A1 (en) 2016-03-24
CN107073015A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12016502354A1 (en) Pharmaceutical composition
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
NZ630392A (en) Methods of treating lung cancer
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12016502352A1 (en) Pharmaceutical composition
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
TW201613578A (en) Pharmaceutical combinations
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
PH12017500505A1 (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
EA202091618A1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.